The effect of donepezil on the persistent cognitive executive function deficit in traumatic brain injury patients

Phase 2

Conditions: persistent cognitive executive function deficit in traumatic brain injury patients.
Intracranial injury

Registration Number: IRCT20130416013027N4

Lead Sponsor: Rasht University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 17

Inclusion Criteria

Patients with all severities of TBI
Patients aged 18 to 60 years
Patients with GOS 4 and 5
Consciousness level of10 to 15
At leaast 4 years of formal education
MMSE score between 17-23
At least 3 months after discharge from hospital due to TBI

Exclusion Criteria

History of neurological diseases
History of mental disorder and use of antipsychotic and antidepressant drugs, drug abuse while studying or last few months
Cognitive and verbal disorders before TBI and sensory deprivations such as deafness and blindness, clinical instability or behavioral problems that prevent the subject from participating in the intervention
Patient dissatisfaction with continuing to participate in the study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive executive function deficit. Timepoint: Before starting study and one month after starting study. Method of measurement: Before the intervention, the patients' cognitive level is determined by the physician using the Persian version of MMSE. The Digital Signal-Stop Executive Function Test Form is used to assess inhibitory control and executive function and information processing speed . In this test, the response time and accuracy of the response are measured. Digital tests to measure cognitive dimensions and information processing speed and performance, such as the Tower of London test (TLT), Cambridge gambling test (CGT), continuing performance test (CPT), lawton daily life activity test (IADL) are performed at the beginning and the end of the last treatment session.

Secondary Outcome Measures